Detalles de la búsqueda
1.
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Lancet
; 384(9944): 665-73, 2014 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24933332
2.
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
Clin Lung Cancer
; 19(3): 270-279.e3, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29373274
3.
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
Lung Cancer
; 112: 126-133, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29191585
4.
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Lung Cancer
; 93: 95-103, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26898621
Resultados
1 -
4
de 4
1
Próxima >
>>